VEGF-BINDING POLYPEPTIDE

• Main Authors: MATSUMOTO TOMOE, OKAMOTO MASAJI, ASANO MAKOTO, NIWA MIKIO, SEGAWA TOSHIAKI, SHIBUYA MASASHI
• Format: Patent
• Language: English
• Published: 17.06.1997
• Edition: 6
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; DERIVATIVES THEREOF; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; NUCLEIC ACIDS; NUCLEOSIDES; NUCLEOTIDES; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES USING MICROORGANISMS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; SUGARS; TESTING; VINEGAR; WINE

PROBLEM TO BE SOLVED: To obtain a new polypeptide capable of binding to the vascular endothelial cell growth factor (VEGF) to inhibit its activity and inhibit vascularization caused by the stimulation action of the VEGF, and capable of being thereby utilized for the treatments of diseases accompanied by the vascularization, such as solid cancers. SOLUTION: This VEGF-binding polypeptide is a new polypeptide capable of binding to the VEGF to inhibit the activity of the VEGF, containing the first immunoglobulin-like domain and the second lmmunoglobulin-like domain in the extracellular region of the VEGF receptor FLT, and not containing the sixth lmmunoglobulin-like domain and the seventh immunoglobulin-like domain. The polypeptide is useful as a VEGF-inhibiting agent capable of inhibiting vascularization caused by the stimulation action of the VEGF and capable of being utilized for the treatments of diseases accompanied by the vascularization, such as solid cancers, etc.